FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jan Ostergren

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Co-author Network

Publications

TOP 3
Cono A Ariti; John G F Cleland; Christopher B Granger; John J V McMurray; Eric L Michelson; Jan Ostergren; Marc A Pfeffer; Stuart J Pocock; Karl Swedberg; Salim Yusuf
Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program.
Bradi B Granger; Inger Ekman; Christopher B Granger; Jan Ostergren; Bertil Olofsson; Eric Michelson; John J V McMurray; Salim Yusuf; Marc A Pfeffer; Karl Swedberg
Adherence to medication according to sex and age in the CHARM programme.
David Preiss; Sofia Zetterstrand; John J V McMurray; Jan Ostergren; Eric L Michelson; Christopher B Granger; Salim Yusuf; Karl Swedberg; Marc A Pfeffer; Hertzel C Gerstein; Naveed Sattar
Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jan Ostergren (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Cono A Ariti; John G F Cleland; Christopher B Granger; John J V McMurray; Eric L Michelson; Jan Ostergren; Marc A Pfeffer; Stuart J Pocock; Karl Swedberg; Salim Yusuf
Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program.
American heart journal 2011;162(5):900-6.
2009: Bradi B Granger; Inger Ekman; Christopher B Granger; Jan Ostergren; Bertil Olofsson; Eric Michelson; John J V McMurray; Salim Yusuf; Marc A Pfeffer; Karl Swedberg
Adherence to medication according to sex and age in the CHARM programme.
European journal of heart failure 2009;11(11):1092-8.
2009: David Preiss; Sofia Zetterstrand; John J V McMurray; Jan Ostergren; Eric L Michelson; Christopher B Granger; Salim Yusuf; Karl Swedberg; Marc A Pfeffer; Hertzel C Gerstein; Naveed Sattar
Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program.
Diabetes care 2009;32(5):915-20.
2008: Peter A Meredith; Jan Ostergren; Inder Anand; Margareta Puu; Scott D Solomon; Eric L Michelson; Bertil Olofsson; Christopher B Granger; Salim Yusuf; Karl Swedberg; Marc A Pfeffer; John J V McMurray
Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program.
Journal of the American College of Cardiology 2008;52(24):2000-7.
2008: Stuart J Pocock; John J V McMurray; Joanna Dobson; Salim Yusuf; Christopher B Granger; Eric L Michelson; Jan Ostergren; Marc A Pfeffer; Scott D Solomon; Stefan D Anker; Karl B Swedberg
Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.
European heart journal 2008;29(21):2641-50.
2008: Jasmine Grewal; Robert S McKelvie; Hans Persson; Peter Tait; Jonas Carlsson; Karl Swedberg; Jan Ostergren; Eva Lonn
Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction.
The American journal of cardiology 2008;102(6):733-7.
2008: Peter S Sever; Neil R Poulter; Bjorn Dahlof; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku S Nieminen; Eoin T O'Brien; Jan Ostergren
The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure.
European heart journal 2008;29(4):499-508.
2007: Eileen O'Meara; Tim Clayton; Margaret B McEntegart; john mcmurray; Ileana L Piña; Christopher B Granger; Jan Ostergren; Eric L Michelson; Scott D Solomon; Stuart Pocock; Salim Yusuf; Karl Swedberg; Marc A Pfeffer
Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.
Circulation 2007;115(24):3111-20.
2007: Nathaniel M Hawkins; Duolao Wang; john mcmurray; Marc A Pfeffer; Karl Swedberg; Christopher B Granger; Salim Yusuf; Stuart J Pocock; Jan Ostergren; Eric L Michelson; Francis G Dunn
Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme.
European journal of heart failure 2007;9(5):510-7.
2007: Nathaniel M Hawkins; Duolao Wang; john mcmurray; M A Pfeffer; K Swedberg; C B Granger; Salim Yusuf; Stuart J Pocock; Jan Ostergren; Eric L Michelson; Francis G Dunn
Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme.
Heart (British Cardiac Society) 2007;93(1):59-64.
2006: Peter S Sever; Björn Dahlöf; Neil Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminem; Eoin O'Brien; Jan Ostergren
Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial.
European heart journal 2006;27(24):2982-8.
2006: Peter A Meredith; Jan Ostergren
From hypertension to heart failure -- are there better primary prevention strategies?
Journal of the renin-angiotensin-aldosterone system : JRAAS 2006;7(2):64-73.
2006: john mcmurray; James B Young; Mark E Dunlap; Christopher B Granger; James Hainer; Eric L Michelson; Steven Earle; Bertil Olofsson; Jan Ostergren; Salim Yusuf; Karl Swedberg; Marc A Pfeffer
Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
American heart journal 2006;151(5):985-91.
2006: Eileen O'Meara; Tim Clayton; Margaret B McEntegart; john mcmurray; Chim C Lang; Simon D Roger; James B Young; Scott D Solomon; Christopher B Granger; Jan Ostergren; Bertil Olofsson; Eric L Michelson; Stuart Pocock; Salim Yusuf; Karl Swedberg; Marc A Pfeffer
Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program.
Circulation 2006;113(7):986-94.
2006: Hans L Hillege; Dorothea Nitsch; Marc A Pfeffer; Karl Swedberg; john mcmurray; Salim Yusuf; Christopher B Granger; Eric L Michelson; Jan Ostergren; Jan Hein Cornel; Dick De Zeeuw; Stuart Pocock; Dirk J van Veldhuisen
Renal function as a predictor of outcome in a broad spectrum of patients with heart failure.
Circulation 2006;113(5):671-8.
2006: Stuart J Pocock; Duolao Wang; Marc A Pfeffer; Salim Yusuf; john mcmurray; Karl B Swedberg; Jan Ostergren; Eric L Michelson; Karen S Pieper; Christopher B Granger
Predictors of mortality and morbidity in patients with chronic heart failure.
European heart journal 2006;27(1):65-75.
2005: Catherine Demers; john mcmurray; Karl Swedberg; Marc A Pfeffer; Christopher B Granger; Bertil Olofsson; Robert S McKelvie; Jan Ostergren; Eric L Michelson; Peter A Johansson; Duolao Wang; Salim Yusuf
Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure.
JAMA : the journal of the American Medical Association 2005;294(14):1794-8.
2005: Neil R Poulter; Hans Wedel; Björn Dahlöf; Peter S Sever; D Gareth Beevers; Mark Caulfield; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren; Stuart Pocock
Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA).
Lancet 2005;366(9489):907-13.
2005: Björn Dahlöf; Peter S Sever; Neil R Poulter; Hans Wedel; D Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.
Lancet 2005;366(9489):895-906.
2005: Salim Yusuf; Jan Ostergren; Hertzel C Gerstein; Marc A Pfeffer; Karl Swedberg; Christopher B Granger; Bertil Olofsson; Jeffrey L Probstfield; John V McMurray
Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure.
Circulation 2005;112(1):48-53.
2005: Eileen O'Meara; Eldrin Lewis; Chris Granger; Mark E Dunlap; Robert S McKelvie; Jeffrey L Probstfield; James B Young; Eric L Michelson; Jan Ostergren; Jonas Carlsson; Bertil Olofsson; john mcmurray; Salim Yusuf; Karl Swedberg; Marc A Pfeffer
Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.
European journal of heart failure 2005;7(4):650-6.
2005: Peter S Sever; Neil R Poulter; Björn Dahlöf; Hans Wedel; Rory Collins; Gareth Beevers; Mark Caulfield; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
Diabetes care 2005;28(5):1151-7.
2004: James B Young; Mark E Dunlap; Marc A Pfeffer; Jeffrey L Probstfield; Alain Cohen-Solal; Rainer Dietz; Christopher B Granger; Jaromir Hradec; Jerzy Kuch; Robert S McKelvie; john mcmurray; Eric L Michelson; Bertil Olofsson; Jan Ostergren; Peter Held; Scott D Solomon; Salim Yusuf; Karl Swedberg
Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
Circulation 2004;110(17):2618-26.
2004: Peter S Sever; Björn Dahlöf; Neil R Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
Drugs 2004;64 Suppl 2():43-60.
2003: Salim Yusuf; Marc A Pfeffer; Karl Swedberg; Christopher B Granger; Peter Held; john mcmurray; Eric L Michelson; Bertil Olofsson; Jan Ostergren
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.
Lancet 2003;362(9386):777-81.
2003: Christopher B Granger; john mcmurray; Salim Yusuf; Peter Held; Eric L Michelson; Bertil Olofsson; Jan Ostergren; Marc A Pfeffer; Karl Swedberg
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.
Lancet 2003;362(9386):772-6.
2003: john mcmurray; Jan Ostergren; Karl Swedberg; Christopher B Granger; Peter Held; Eric L Michelson; Bertil Olofsson; Salim Yusuf; Marc A Pfeffer
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.
Lancet 2003;362(9386):767-71.
2003: Marc A Pfeffer; Karl Swedberg; Christopher B Granger; Peter Held; john mcmurray; Eric L Michelson; Bertil Olofsson; Jan Ostergren; Salim Yusuf; Stuart Pocock
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.
Lancet 2003;362(9386):759-66.
2003: john mcmurray; Jan Ostergren; Marc Pfeffer; Karl Swedberg; Chris Granger; Salim Yusuf; Peter Held; Eric L Michelson; Bertil Olofsson
Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme.
European journal of heart failure 2003;5(3):261-70.
2003: Peter S Sever; Björn Dahlöf; Neil R Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
Lancet 2003;361(9364):1149-58.
2002: Jackie Bosch; Salim Yusuf; Janice Pogue; Peter Sleight; Eva Lonn; Badrudin Rangoonwala; Richard Davies; Jan Ostergren; Jeffrey L Probstfield
Use of ramipril in preventing stroke: double blind randomised trial.
BMJ (Clinical research ed.) 2002;324(7339):699-702.
2001: Peter S Sever; Björn Dahlöf; Neil R Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Anglo-Scandinavian Cardiac Outcomes Trial: a brief history, rationale and outline protocol.
Journal of human hypertension 2001;15 Suppl 1():S11-2.
2001: Peter S Sever; Björn Dahlöf; Neil R Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators.
Journal of hypertension 2001;19(6):1139-47.
1999: Karl Swedberg; M Pfeffer; Chris Granger; Peter Held; john mcmurray; G Ohlin; B Olofsson; Jan Ostergren; Salim Yusuf
Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators.
Journal of cardiac failure 1999;5(3):276-82.
1997: Björn Dahlöf; Lars H Lindholm; S Carney; P J Pentikäinen; Jan Ostergren
Main results of the losartan versus amlodipine (LOA) study on drug tolerability and psychological general well-being. LOA Study Group.
Journal of hypertension 1997;15(11):1327-35.